Fingolimod attenuates gait deficits in mice subjected to experimental autoimmune encephalomyelitis

Gracious D.S. Kasheke; Scott P. Holman; George S. Robertson

doi:10.1016/j.jneuroim.2022.577926

Fingolimod attenuates gait deficits in mice subjected to experimental autoimmune encephalomyelitis

Gracious D.S. Kasheke, Scott P. Holman, George S. Robertson

Medicine

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Fingolimod, used to treat relapsing-remitting multiple sclerosis (RRMS), reduces motor deficits in mice with established experimental autoimmune encephalomyelitis (EAE). To better characterize the therapeutic effects of fingolimod, kinematic gait analysis was employed to precisely measure movements of a hindleg while EAE mice walked on a treadmill. Relative to the vehicle group, oral dosing with fingolimod, beginning after disease onset (1 mg/kg/day), increased hip heights and knee joint movements, and reduced spinal cord demyelination. These findings suggest that fingolimod preserves gait in RRMS patients by protecting motor circuits in the spinal cord.

Original language	English
Article number	577926
Journal	Journal of Neuroimmunology
Volume	370
DOIs	https://doi.org/10.1016/j.jneuroim.2022.577926
Publication status	Published - Sept 15 2022

Bibliographical note

Funding Information:
This work was supported by funding from the Congressionally Directed Medical Research Program (Award number: W81XWH1910579 ).

Publisher Copyright:
© 2022 Elsevier B.V.

ASJC Scopus Subject Areas

Immunology and Allergy
Immunology
Neurology
Clinical Neurology

PubMed: MeSH publication types

Journal Article
Research Support, U.S. Gov't, Non-P.H.S.

Access to Document

10.1016/j.jneuroim.2022.577926

Cite this

@article{d6475612c1b5483eaaca67ce3b3bba44,

title = "Fingolimod attenuates gait deficits in mice subjected to experimental autoimmune encephalomyelitis",

abstract = "Fingolimod, used to treat relapsing-remitting multiple sclerosis (RRMS), reduces motor deficits in mice with established experimental autoimmune encephalomyelitis (EAE). To better characterize the therapeutic effects of fingolimod, kinematic gait analysis was employed to precisely measure movements of a hindleg while EAE mice walked on a treadmill. Relative to the vehicle group, oral dosing with fingolimod, beginning after disease onset (1 mg/kg/day), increased hip heights and knee joint movements, and reduced spinal cord demyelination. These findings suggest that fingolimod preserves gait in RRMS patients by protecting motor circuits in the spinal cord.",

author = "Kasheke, {Gracious D.S.} and Holman, {Scott P.} and Robertson, {George S.}",

note = "Funding Information: This work was supported by funding from the Congressionally Directed Medical Research Program (Award number: W81XWH1910579 ). Publisher Copyright: {\textcopyright} 2022 Elsevier B.V.",

year = "2022",

month = sep,

day = "15",

doi = "10.1016/j.jneuroim.2022.577926",

language = "English",

volume = "370",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

}

TY - JOUR

T1 - Fingolimod attenuates gait deficits in mice subjected to experimental autoimmune encephalomyelitis

AU - Kasheke, Gracious D.S.

AU - Holman, Scott P.

AU - Robertson, George S.

PY - 2022/9/15

Y1 - 2022/9/15

N2 - Fingolimod, used to treat relapsing-remitting multiple sclerosis (RRMS), reduces motor deficits in mice with established experimental autoimmune encephalomyelitis (EAE). To better characterize the therapeutic effects of fingolimod, kinematic gait analysis was employed to precisely measure movements of a hindleg while EAE mice walked on a treadmill. Relative to the vehicle group, oral dosing with fingolimod, beginning after disease onset (1 mg/kg/day), increased hip heights and knee joint movements, and reduced spinal cord demyelination. These findings suggest that fingolimod preserves gait in RRMS patients by protecting motor circuits in the spinal cord.

AB - Fingolimod, used to treat relapsing-remitting multiple sclerosis (RRMS), reduces motor deficits in mice with established experimental autoimmune encephalomyelitis (EAE). To better characterize the therapeutic effects of fingolimod, kinematic gait analysis was employed to precisely measure movements of a hindleg while EAE mice walked on a treadmill. Relative to the vehicle group, oral dosing with fingolimod, beginning after disease onset (1 mg/kg/day), increased hip heights and knee joint movements, and reduced spinal cord demyelination. These findings suggest that fingolimod preserves gait in RRMS patients by protecting motor circuits in the spinal cord.

UR - http://www.scopus.com/inward/record.url?scp=85134268391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85134268391&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2022.577926

DO - 10.1016/j.jneuroim.2022.577926

M3 - Article

C2 - 35863299

AN - SCOPUS:85134268391

SN - 0165-5728

VL - 370

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

M1 - 577926

ER -

Fingolimod attenuates gait deficits in mice subjected to experimental autoimmune encephalomyelitis

Abstract

Bibliographical note

ASJC Scopus Subject Areas

PubMed: MeSH publication types

Access to Document

Other files and links

Fingerprint

Cite this